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ABSTRACT 
Cognition and social behaviour in schizophrenia 
An animal  mode l  inves t igat ing  the  potential  rol e  of  
n i tr i c  oxide  
 
Caroline Wass 
Institute of Neuroscience and Physiology, Section for Pharmacology, 
the Sahlgrenska Academy at Göteborg University,  Sweden 
 
Cognitive deficits are the single strongest predictor of functional outcome 
in patients with schizophrenia. Furthermore, these deficits are not 
satisfactorily alleviated by available antipsychotic treatment. Functional 
outcome is also dependent upon social functioning and patients with 
schizophrenia display social dysfunctions including specific impairment in 
social cognition. Thus, cognitive deficits and social dysfunctions make up 
core symptoms of schizophrenia that needs to be further investigated in 
order to find novel treatment targets. Phencyclidine (PCP) is a 
psychotomimetic compound that produces symptoms in humans that 
closely resemble schizophrenia. Consequently, the PCP-model is 
consistently used for studying schizophrenia in experimental animals. 
Previous studies from our lab demonstrate that PCP-induced deficits in 
several translational animal models of schizophrenia can be blocked by 
inhibition of nitric oxide (NO) production. Such PCP-induced deficits 
range from impairment in pre-cognitive (pre-attentive) sensory information 
processing and habituation of acoustic startle to selective attention. In 
addition, several clinical studies indicate that the NO-signalling pathway 
may be involved in the pathophysiology of schizophrenia.  
 
The overall aim of this thesis was to investigate the effects of PCP and NO 
synthase (NOS) inhibition on higher order cognitive functions, i.e. 
memory, and social interaction. Therefore, we investigated the effects of 
PCP and the NOS-inhibitor, NG-nitro-L-arginine methyl ester (L-NAME) 
on; (1) spatial learning, working memory, long-term memory, and cognitive 
flexibility using different versions of the Morris water maze, and (2) social 
function and memory using a social interaction paradigm.  
 
The results demonstrate that acute PCP-treatment impaired spatial 
learning, working memory, long-term memory, and cognitive flexibility in 
rats. These PCP-induce deficits were normalized by pretreatment with the 
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NOS-inhibitor, L-NAME. Furthermore, PCP-treatment decreased time 
spent in social interaction, a deficit that was independent of motor activity 
and frequency of interactions. This social interaction deficit was blocked 
by NOS-inhibition.  
 
Taken together these results suggest that the effects of PCP, on cognitive 
functioning and social interaction, depend on the NO-signalling system. In 
addition, several studies from our research group show that systemic PCP-
treatment in fact seems to increase NO production in the rodent brain. 
Based on these findings, in addition to the results from this thesis, we 
propose a “NO-dysregulation hypothesis for schizophrenia”. Moreover, 
this hypothesis suggests that the NO-signalling pathway may be a potential 
new treatment target for schizophrenia. 
 
Key words: schizophrenia, cognition, memory, Morris water maze, social 
function, social interaction, phencyclidine, nitric oxide, L-NAME, rat. 
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ABBREVIATIONS 
AMPA/R α-amino-3-hydroxy-5-hydroxy-5-methyl-4-
isoxazoleproprionate/receptor 
Ca2+ calcium 
cAMP cyclic adensoine monophosphate 
cGMP cyclic guanosine monophosphate  
COMT  catechol-O-methyltransferase  
CA1 cornu ammonis 1 
DA/R dopamine/receptor 
D1R dopamine D1 receptor 
D2R dopamine D2 receptor 
D5R dopamine D5 receptor 
eNOS endothelial nitric oxide synthase 
GABA/R γ-ammino-butyric acid/receptor 
GTP guanosine triphospahte 
iNOS inducible nitric oxide synthase 
L-NAME NG-nitro-L-arginine methyl ester 
LTP long-term potentiation 
mGlu/R metabotropic glutamate/receptor 
MWM   Morris water maze 
nNOS neuronal nitric oxide synthase 
NADPH nicotinamide adenine dinucleotide phosphate-oxidase 
NMDA/R N-methyl-D-aspartate/receptor 
NO nitric oxide 
NOS nitric oxide synthase 
PCP phencyclidine 
PFC prefrontal cortex 
PPI prepulse inhibiton 
SAL saline (sodium chloride) 
sGC soluable guanylyl cyclase 
5-HT/R 5-hydroxytryptamine, i.e. serotonin/receptor 
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BACKGROUND 
Dementia praecox, i.e.” premature dementia” was first described by 
Czechoslovakian psychiatrist Arnold Pick in a case study of a patient that 
displayed a hebephrenic type of psychosis (Pick, 1891). Psychiatrist Emil 
Kraepelin, was the first to acknowledge psychiatric disorders from a 
biological perspective, and further established the term dementia praecox. In 
1911, the Swiss psychiatrist Paul Eugen Bleuler renamed dementia praecox  
as “the group of schizophrenias” and described it as a cluster of disorders 
rather than one coherent disease (Adityanjee et al., 1999). The name 
schizophrenia stems from Greek and implies “split mind”. The group of 
schizophrenias was characterized as sharing basic symptoms, such as 
splitting or fragmentation of the mind, disordered train of mental 
associations and derangement of thoughts. Thus, there has been an 
emphasis on both the cognitive aspects, as well as the heterogeneity, of this 
disorder, or group of disorders, since it was first described. 
 
Schizophrenia affects approximately 1% of the population worldwide and 
is a chronic, severe disorder, lacking curative treatment. The suicide rate is 
as high as 9-13%, with the incidence of suicide attempt reaching 50% of 
diagnosed patients over a lifetime (Caldwell and Gottesman, 1990, Perenyi 
and Forlano, 2005). The onset of schizophrenia usually occurs around 18-
25 years of age and is often preceded by premorbid behavioural deviations, 
such as social withdrawal and affective changes (Keshavan et al., 2005). 
Furthermore, most patients diagnosed with schizophrenia never return to 
school or work (Marwaha and Johnson, 2004).  
Symptoms 
The symptoms of schizophrenia are commonly divided into three 
categories namely; positive symptoms, negative symptoms, and cognitive 
deficits (Green, 1996, Fuller, 2003).  
Positive symptoms  
Positive symptoms are characterized by functions and behaviours that are 
displayed in addition to normal functioning, thereof the term “positive” 
meaning “extra”. Hallucinations, delusions and disorganized behaviour are 
often the type of symptom that brings the patient to the emergency room 
and qualify her or him as ill. Hallucinations most often occur within the 
auditory domain, such as “hearing voices” that are often of an unpleasant 
and disparaging nature. Delusions may be grandiose or paranoid and can 
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become very disabling, as they are incorporated in, and govern, daily living. 
The positive symptoms are cyclic in nature and are alleviated reliably by 
available antipsychotic treatment (Capuano et al., 2002).  
Negative symptoms  
In contrast to the positive symptoms, negative symptoms are characterized 
by loss of “normal” functioning, are chronic, and include anhedonia (loss 
of pleasurable feelings), flattened affect (e.g. blunted emotions), avolition 
(lack of initiative), and social withdrawal. Social withdrawal and lack of 
social cognition may in fact be a symptom category of its own. These 
losses of functioning closely resemble the symptoms apparent in states of 
clinical depression. In general, negative symptoms are at best only partially 
alleviated by available antipsychotic treatment (Murphy et al., 2006, Stahl 
and Buckley, 2007). It has even been suggested that negative symptoms are 
worsened by antipsychotic treatment (i.e. neuroleptic-induced dysphoria) as 
blockade of the dopamine (DA)ergic reward system seems to attenuate 
feelings of reward (Kirsch et al., 2007).  
 
There has previously been some deliberation in the literature as to whether 
or not negative symptoms include cognitive deficits. Extensive research 
indicates that cognitive deficits should be regarded as a separate group of 
deficits. Compared to e.g. affective changes, cognitive deficits have a 
distinct neuroanatomical basis (Menon et al., 2001, Honey et al., 2003).  
Cognitive deficits 
As early as the late 19th century, Kraepelin emphasized the importance of 
cognitive deficits as a significant part of schizophrenia, indicated by the 
term “premature dementia”.  This important core deficit was then 
somewhat ignored in the favour of positive symptoms, since the positive 
symptoms were treated successfully with chlorpromazine. After the 
breakthrough of chlorpromazine, psychotic symptoms could be treated 
pharmacologically instead of using ethically questionable strategies such as 
lobotomy and insulin shock. In this last decade, there has been an 
increasing interest in studying cognitive dysfunctions, as they have been 
found to be predictive of both disease outcome and treatment response 
(Green, 1996, Green, 2006, Helldin et al., 2007, Lewis, 2004). Cognitive 
deficits include difficulties with attention, language, several aspects of 
memory, executive functioning, cognitive flexibility, and interpretation of 
social cues (Conklin et al., 2005, Couture et al., 2006, Green, 2006, Hill et 
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al., 2004, Karilampi et al., 2007, Swerdlow et al., 1996). Cognitive deficits 
are not satisfactorily alleviated by available antipsychotic treatment. Hence, 
there is a pressing need to develop effective pharmacological interventions 
for treating this category of disabling deficits (Green and Braff, 2001). 
Aetiology   
The aetiology of schizophrenia remains unknown and given the 
heterogeneous nature of the disorder it is likely that there are multiple 
contributing aetiological factors. The single strongest predictive factor for 
developing schizophrenia is a family history including a first degree relative 
with the disorder (Hallmayer, 2000). Monozygotic twins show a 48% 
concordance rate for schizophrenia and having a parent with schizophrenia 
means a 13% risk of developing the disorder. So far no single predictive 
gene has been discovered, but there are several candidate genes that 
predispose an individual to the disorder (see Table 1 adapted from Stahl, 
2007, McClellan et al., 2007).  
 
 
 
Table 1: Susceptibility genes for schizophrenia, adopted from Stahl (2007). 
 
Several environmental risk factors for developing schizophrenia have been 
proposed, such as urban living, immigrant status, and expressed emotion 
within the family, with varying results (Kavanagh, 1992, Freeman, 1994, 
McDonald and Murray, 2000). Moreover, seasonal birth, maternal 
influenza, delivery complications, and nutritional restriction are predictors 
Susceptibility genes for schizophrenia
AKT1 D3R
BDNF MUTED
CHRNA7 MRDS1
COMT MAO-A
DAAO Nur77
DAOA Neuregulin
DISC-1 PPP3CC
Dysbindin PRODH2
GAD1 RGS4
GRM3 Tyrosine hydroxylase
Erb-B4 Spinophylin
D2R FEZ1
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of increased risk for schizophrenia in adult life. These risk factors support 
a neurodevelopmental theory of schizophrenia (see “Neurodevelopmental 
hypothesis”, page 19, Lewis and Levitt, 2002).  
 
Another possible aetiological factor for schizophrenia may be cannabis 
abuse. Patients seeking help for cannabis-dependence were found to have 
an increased incidence of previous psychiatric diagnosis, e.g. schizophrenia, 
in comparison to controls, indicating co-morbidity of these disorders 
(Arendt et al., 2007). In another Danish register study, cannabis-induced 
psychotic disorder was found to predispose individuals to develop long 
lasting psychotic disorders in almost 50% of the patients (Arendt et al., 
2005). Furthermore, several studies have established a causal association 
between cannabis abuse and development of psychosis (Palsson et al., 
1982, Andreasson et al., 1987, Arseneault et al., 2004), an association that is 
further influenced by allelic composition of the catechol-O-
methyltransferase (COMT) gene (Caspi et al., 2005).  
Dopamine hypothesis 
In 1947, the French surgeon Henri Laborit, discovered the antipsychotic 
effect of chlorpromazine in patients with schizophrenia (Coirault et al., 
1956). The mechanism of action of chlorpromazine however, was going to 
remain unknown for almost two decades. In 2000, Arvid Carlsson was 
awarded the Nobel Prize for his discoveries concerning DA as a 
neurotransmitter essential for motor function and as the main target 
transmitter system of antipsychotic treatment (Carlsson, 1959, Carlsson 
and Lindqvist, 1963). The role of DA in the central nervous system was 
first described by Arvid Carlsson and co-workers in 1950s´ (Carlsson et al., 
1958, Carlsson et al., 1957, Carlsson, 1959). Since then, DA has been 
found to be involved in several other brain functions, such as reward 
mechanisms and cognition. Dysfunctions of the DA systems may cause 
diseases such as addictive behaviours, including compulsive over eating, 
pathological gambling, drug addiction, but also Parkinsons´ disease 
(Carlson, 1959, Engel and Carlsson, 1977, Ehringer and Hornykiewicz, 
1960, Jerlhag et al., 2007, Liljequist et al., 1977, Volkow et al., 2003). 
 
In the central nervous system, the catecholamine DA, is most abundant in 
the corpus striatum, limbic system, and the hypothalamus. It is less 
abundant in other areas such as the prefrontal cortex (PFC). The four 
major DA pathways are the nigrostriatal-, tuberoinfundibular-, 
mesocortical- and mesolimbic pathways, which all mediate different effects 
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of DA (Stahl, 2002). DA exerts its effects through G-protein coupled 
receptors that are classified into two categories; DA D1 type receptors 
(D1R) and DA D2 type receptors (D2R). The D1R family include D1 and 
D5 receptors and activation of these receptors lead to an activation of 
adenylate cyclase and an increase in adensoine monophosphate  (cAMP).  
production. The D2R family includes D2, D3, and D4 receptors and 
activation results in inhibition of adenylate cyclase resulting in reduction of 
cAMP production and/or increase in inositol triphosphate production 
(Garau et al., 1978, Gingrich and Caron, 1993, Kebabian and Calne, 1979, 
Kebabian and Greengard, 1971).  
 
The DAergic hypothesis of schizophrenia rests mainly on the fact that the 
clinical effects of all antipsychotic medications are blockade of the D2R 
(Nordstrom et al., 1993, Seeman et al., 1976). Further evidence for a 
hyperDAergic state, underlying schizophrenia, comes from observations 
that d-amphetamine can lead to psychosis in healthy subjects (Angrist and 
Gershon, 1970). D-amphetamine exacerbates positive symptoms in 
patients with schizophrenia, which is accompanied by an elevated increase 
in DA release, and over activity of striatal D2Rs, compared to controls 
(Abi-Dargham et al., 1998, Laruelle et al., 2000). Thus, DA is a key player 
in the pathophysiology of schizophrenia specifically regarding the positive 
symptoms.  
 
The “original” DA hypothesis states that schizophrenia stems from a 
hyperDAergic state. There is however accumulating evidence that 
schizophrenia is a DA-dysregulation disorder. Striatal DA activity, 
mediated by D2R, is increased while prefrontal DA activity, transmitted by 
D1R activity, is decreased in schizophrenia (Abi-Dargham, 2004). The 
imbalance in the DA system results from a dysfunctional interplay between 
several neurotransmitter systems, including the γ-ammino-butyric acidergic 
(GABA) and the glutamatergic system (Carlsson et al., 2001). 
Glutamate hypothesis 
Clinical observations from the 1950´s, and onward, showed that the 
dissociative anaesthetic compound Sernyl®, i.e. phencyclidine (PCP), 
induces symptoms in humans that closely resemble schizophrenia. These 
symptoms incorporate positive symptoms, negative symptoms, and 
cognitive deficits (Allen and Young, 1978, Luby et al., 1959, Yesavage and 
Freman, 1978). PCP mainly exerts its pharmacological effects through the 
glutamatergic system. Based on these findings, PCP is thought to induce 
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some of the underlying pathophysiological mechanisms involved in 
schizophrenia (Javitt and Zukin, 1991, Olney et al., 1999). 
 
Glutamate is the most abundant excitatory amino acid transmitter of the 
brain (Curtis et al., 1959, Watkins, 2000). Glutamate, besides serving as an 
important metabolic contributor, exerts its effect as a neurotransmitter via 
acting on four different kinds of receptors, namely N-methyl-D-aspartate 
(NMDA), α-amino-3-hydroxy-5-hydroxy-5-methyl-4-isoxazoleproprionate 
(AMPA), kainate and metabotropic (mGlu) receptors. The NMDA, AMPA 
and kainate receptors are ionotrophic receptors, permeable to Ca2+, NA+ 
and K+, while the metabotrophic receptor acts via intracellular second 
messenger systems that mediate e.g. intracellular Ca2+ release (Schoepp, 
2001, Thornberg and Saklad, 1996).  
 
The NMDA receptor (NMDAR), in cooperation with the AMPA receptor 
(AMPAR), play an important role in cognitive functioning such as learning 
and memory (Robbins and Murphy, 2006). These two receptors are 
furthermore associated with schizophrenia (as reviewed in Kristiansen et 
al., 2007). Moreover, several susceptibility genes, regulating 
neurodevelopmental molecular processes, synaptogenesis and NMDAR 
functioning in schizophrenia have been discovered (Stahl, 2007). These 
findings suggest a coherent hypothesis merging genetic susceptibility, 
neurodevelopmental abnormalities, pathological neurocircuitry changes, 
and information processing deficits together with glutamateric 
abnormality, in revealing schizophrenia.  
 
NMDARs are widely distributed throughout the brain, with the highest 
density in the hippocampus, nucleus accumbens, and the PFC (Monaghan 
and Cotman, 1985). NMDARs are localized on both neurons and glial cells 
(Verkhratsky and Kirchhoff, 2007) and are involved in several essential 
neural functions such as cerebrovascular dilation (Busija et al., 2007) and 
neuronal plasticity including long-term synaptic changes (Lau and Zukin, 
2007, Rao and Finkbeiner, 2007). The psychotomimtetic compounds, PCP 
and ketamine, are non-competitive NMDAR antagonists that bind the 
PCP site in the ion channel and thereby block cation passage. 
 
Further support for the hypoglutamatergic hypothesis of schizophrenia, 
was produced by Kim and co-workers (1980), as they found lower levels of 
glutamate in cerebrospinal fluid of patients with schizophrenia compared 
to controls. These findings have not been consistently replicated and 
therefore remain controversial (Hashimoto et al., 2005a).   
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A new interesting hypoglutamatergic hypothesis has been proposed 
involving the endogenous NMDAR antagonist, kynurenic acid, in 
schizophrenia (Erhardt et al., 2007). Patients with schizophrenia are found 
to have increased levels of kynurenic acid both in the brain and in 
cerebrospinal fluid in comparison with controls (Erhardt et al., 2001, 
Nilsson, 2005 #377, Nilsson et al., 2005, Schwarcz et al., 2001). 
 
Evidently there is accumulated support for a dysregulated glutamatergic 
system involved in schizophrenia. However, it is not clear whether a 
dysfunctional glutamatergic system is the primary cause of the disease, 
giving rise to the DAergic imbalance, or vice versa. 
Glutamate-dopamine imbalance  
Glutamatergic and DAergic pathways make up an intricate network of 
subcortical – cortical connections, in which subcortical DA release is 
modulated by e.g. glutamate. The midbrain ventral tegmental area and 
substantia nigra DAergic activity is modulated by both activation and 
inhibition of projections ascending from the PFC (Sesack and Carr, 2002). 
The activating PFC projections are glutamatergic and synapse right on to 
DAergic neurons, while the inhibiting pathways are glutamatergic 
modulations of DA cells via GABAergic interneurons (Carlsson et al., 
1999, Carlsson and Carlsson, 1990, Carlsson et al., 2001). From the 
hippocampus there are excitatory afferent projections to the PFC (Carr 
and Sesack, 1996) and these projections are abnormal in patients with 
schizophrenia (Arnold et al., 1995). 
 
Thus, a dysregulation hypothesis of these cortical-subcortical, DAergic and 
glutamatergic projections, including the PFC, striatu,m and hippocampus, 
is proposed for schizophrenia (Schultz and Andreasen, 1999, Arnold et al., 
1995, Carlsson et al., 1997, Javitt, 2007) 
 
Besides DA and glutamate, several other neurotransmitter systems are 
involved in the pathophysiology of schizophrenia, such as the 5-HT-, 
noradrenaline-, acetylcholine-, and nitric oxide (NO) signalling system. 
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Neurodevelopmental hypothesis 
Neuoranatomical studies of patients with schizophrenia have consistently 
shown enlarged ventricles, reduced brain volume, abnormal hippocamal 
volume, and deviant layering of the cortex (Bogerts et al., 1990, Chana et 
al., 2003, Chance et al., 2004, Weinberger et al., 1979). A study by Susser 
and Lin (1992) showed that children of pregnant mothers who were 
victims of starvation during the Dutch famine, 1944-45, displayed an 
increased incidence of schizophrenia in adult life. These findings have been 
replicated in a Chinese cohort study (St Clair et al., 2005). Birth 
complications such as hypoxia and maternal influenza, during the second 
trimester of pregnancy, have been found to correlate with increased 
incidence of schizophrenia in offspring (Mednick et al., 1988, Cannon et 
al., 2000, Rosso et al., 2000). Such findings have led to a neuro-
developmental hypothesis for schizophrenia, suggesting that schizophrenia 
is a disorder of abnormal perinatal neurodevelopment, although no certain 
causal relationships have been established between these risk factors and 
the development of schizophrenia. None of the risk factors seem to be 
sufficient or necessary for developing schizophrenia later in life, but in 
combination with other vulnerability factors, e.g. genetic heritability, the 
risk may be increased (Figure 1).  
Figure 1: Risk factors adding to genetic predisposition for developing schizophrenia, 
adapted from Sullivan (2005). 
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Nitric oxide and schizophrenia 
NO is a gaseous molecule involved in several important physiological 
functions, such as immunological response, platelet aggregation, dilation of 
smooth muscle, neuroplasticity, neurotransmitter release, and neuro-
development (Ignarro, 1989, Gruetter et al., 1979, Bernstein et al., 2005). 
NO is a reactive gas with a half-life in the range of seconds, that can 
diffuse freely through membranes. Thus, NO may act as both an intra and 
extra cellular communicator. The synthesis of NO occurs through a NO 
synthase (NOS) and calcium-calmodulin-activated chemical reaction using 
L-arginine as the substrate for synthesis, along with oxygen. Synthesis 
involves several cofactors, including NADPH as an essential electron 
donor in the oxidation of L-arginine to NO and L-citrulline (Griffith and 
Stuehr, 1995, Figure 2).  
 
There are three different isoforms of the NOS enzyme; endothelial NOS 
(eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS). The iNOS 
synthesizes NO that is important for immune response and expressed in 
e.g. macrophages and neutrophils. The endothelial form of NOS is 
primarily expressed in vascular endothelial cells, and regulates vascular tone 
(Prickaerts et al., 2004), while the nNOS is mainly expressed in neurons 
(Bredt and Snyder, 1994).  
 
 
Figure 2: NO synthesis and its signalling pathway. 
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Preferentially, NO exerts its function through binding to a heme group, i.e. 
the “NO receptor”, on soluable guanylyl cyclase (sGC) and induces the 
conversion of guanosine triphosphate (GTP) to cyclic guanosine 
monophosphate (cGMP, Figure 2). In brain slices, it has been shown that 
NO-cGMP signal transduction is activated by NMDARs (Hopkins et al., 
1996). 
 
Regarding long-termpotentiation (LTP) in the hippocampus, cGMP exerts 
its effects by regulating cGMP-dependent ion channels and activating 
cGMP-dependent protein kinases, that in turn phosphorylate various 
proteins and affects cAMP concentrations (Leinders-Zufall et al., 1995). 
Endogenous NO also modulates the release of several neurotransmitters 
throughout the brain and exerts modulator effects on 5-HT and DA 
release in e.g. the hippocampus (Wegener et al., 2000, Strasser et al., 1994). 
 
It has been suggested that NO is involved in several aspects of cognition, 
e.g. learning and memory (Bernstein et al., 2005, Zhuo et al., 1994). 
Behavioural studies show that inhibitors of NOS disrupts spatial learning 
(Chapman et al., 1992, Zou et al., 1998) and furthermore, that NOS is 
expressed in e.g. pyramidal neurons of the hippocampus cornu ammonis 1 
(CA1), (Pepicelli et al., 2004). Moreover, the NO-cGMP pathway seems to 
be particularly important for hippocampus-dependent memory (Ingram et 
al., 1998, Mamiya et al., 2000, Zou et al., 1998) as nNOS is co-localized 
with NMDARs and sGC in the CA1 region (Burette et al., 2002). Taken 
together, the NMDAR mediated NO-cGMP signalling pathway of the 
hippocampus seems to be important for learning and memory. 
 
Interestingly, there is accumulating evidence from clinical studies 
suggesting that the NO signalling system is involved in the 
pathophysiology of schizophrenia (Bernstein et al., 2005, for further 
information see “Proposed clinical relevans”, page 57).  
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Disrupted filtering mechanism in schizophrenia: A unifying 
theory? 
Schizophrenia is a heterogeneous disorder encompassing deficits in several 
brain functions reflecting its complex underlying pathophysiology. 
Although there is no proven unifying aetiological hypothesis, a model 
integrating developmental abnormalities with physiological network 
dysfunction and expression of schizophrenic symptoms has been 
proposed. Patients with schizophrenia consistently show deficits in sensory 
information processing, measured by prepulse inhibition (PPI) and 
habituation of acoustic startle (Braff et al., 1992, Swerdlow et al., 1994). 
PPI is a measure of reflexive pre-attentive information processing whereby 
a weak pre-stimulus inhibits the startle response to a following stronger 
stimuli. Habituation is a measure of response learning, as one stimulus 
elicits a progressively weaker startling response when consistently repeated 
(Braff, 1993, Braff et al., 1992). The primary PPI circuit consists of a 
complex network, including cortico-striato-pallido-thalamic neural circuitry 
that is dependent on e.g. DA and glutamate transmission (Johansson et al., 
1994, Koch, 1999, Swerdlow et al., 1994, Zhang et al., 1999).  
 
The hypothesis proposes that pre-attentive sensory information 
processing, measured by e.g. PPI, is necessary for an adequate filtering of 
incoming sensory information. Thus, filtering out irrelevant sensory 
information on a subcortical, pre-attentive level is necessary for the brains´ 
capacity to further process relevant information. Hence, an abnormal 
filtering mechanism, e.g. decreased PPI, could lead to an inability to 
distinguish “relevant” from “irrelevant” sensory information. This could 
cause an overflow of inappropriate information, reaching higher cortical 
areas, resulting in deficits in attention and cognitive abnormalities 
(Andreasen, 2000, Braff, 1993, Geyer, 2006). It is furthermore possible that 
such information overflow could result in additional psychotic symptoms, 
including hallucinations and delusions.  
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This point is further elucidated in the reply given by John Forbes Nash Jr, 
Nobel Prize Winner in Economics 1994, diagnosed with schizophrenia, 
when asked by professor George Mackey:  
 
“How could you, a mathematician, a man devoted to reason and logical proof.. How 
could you believe that extraterrestrials are sending you messages? How could you believe 
that you were being recruited by aliens from outer space to save the world?”. 
 
John Nash Jr replied: 
“ …the ideas I had about supernatural beings came to me the same way that my 
mathematical ideas did. So I took them seriously”.  (Nasar, 1998) 
 
The unifying hypothesis states that environmental and genetic risk factors 
interact during the perinatal period, affecting neurodevelopmental 
physiological processes such as neurogenesis, neuronal migration 
synaptogenesis, and apoptosis. An abnormal neurodevelopment would 
lead to anatomical deviations and inappropriate neuronal networks in the 
adolescent brain. This abnormal physiology could create a vulnerability 
that, later in life and in combination with various environmental factors, 
could lead to development of schizophrenia, Figure 3 (Andreasen, 2000, 
Braff, 1993, Klamer, 2004).  
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Figure 3: Working hypothesis of schizophrenia unifying developmental abnormalities, 
sensory information processing and symptoms of schizophrenia Reference: Klamer (2004) 
modified after Andreasen (2000) and Braff (1993). 
Working model
Etiology (multiple convergent factors )
Pathophysiology
Brain development from conception to early adulthood
exessive synaptic and/or dendritic elimination, neuron formation, migration,
pruning , apoptosis enlarged ventricles , increased neuronal density
and reduced overall brain volume
Neuronal connectivity and communication
anatomic and functional disruption , neurotransitter and 
synaptic dysfunction , hormonal imbalance
Impairment in pre -attentive cognitive processes
information processing , sensorimotor gating
Impairment in second -order cognitive processes
e.g ., attention , memory , language
Symptoms of schizophrenia
e.g ., hallucinations, thought disorder , negative symptoms, cognitive dysfunctions
Genetic factors
DNA, gene expression
Environmental factors
Viruses , toxins, nutrition, pregnancy and
birth complications , psychological experience
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Learning memory and schizophrenia 
Division of memory 
Memory has traditionally been divided into two components; short-term 
and long-term memory. Short-term memory has been defined as transient 
storage, in the range of seconds, with the capacity of holding 7± 2 items. 
The items in short-term memory with repeated exposure would transform 
into long-term memory. Long-term memory could hold an unlimited 
amount of memory for an indefinite amount of time (Miller, 1956, 
Atkinson, 1968). Baddeley and Hitch (1974) further developed this two-
component model into a unifying working memory model, integrating 
short- with long-term memory. Working memory was defined as a three-
component model where phonologic, visual and spatial information would 
be processed under the influence of an attention-steering central executive 
component (Baddeley, 1974). Thus, working memory converged short-
term and long-term memory, involving manipulation of information and 
highlighting the importance of cognitive functioning in memory. Working 
memory is dependent on PFC functioning (Baddeley, 2004).  
 
In 1957, Scoville and Milner described a patient that had lost the capacity 
to form new memories. Patient H.M. had gone through bilateral 
hippocampalectomy due to severe epilepsy. H.M was soon found to be 
unable to form so-called explicit memories, i.e. memories of events and 
facts. However, his implicit memory, i.e. motor learning, was still intact. 
H.M. displayed anterograde but not retrograde amnesia for explicit 
memories. Consequently, the hippocampus was discovered to be necessary 
for the storage of new explicit memories, but not for retrieval of old 
memories. 
Long-term memory is divided up in two main categories of memories; 
explicit (or declarative) and implicit (or non-declarative) memories, Figure 
4. Explicit memories include facts and events, i.e. memories that can be 
“declared” or talked about (Tulving, 2002). This type of memory is, 
dependent upon the medial temporal lobe, as illustrated by H.M. Implicit 
memory includes priming, procedural learning (i.e. motor learning), 
associative learning (e.g. classical conditioning) and non-associative learning 
(such as response habituation, (Squire, 1987).  
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Figure 4: Long-term memory, its subdivisions and the structural anatomy governing these 
functions, adapted from (Squire, 1994). 
Physiology of memory 
The basis for learning and memory is the remarkable plasticity of the brain 
and its inherent capacity to change its structure at the synaptic level. 
Donald O. Hebb´s Law illustrates this point as he described the neural 
basis for long-term memory:  
 
“When an axon of cell A is near enough to excite cell B and repeatedly or persistently 
takes part in firing it, some growth process or metabolic change takes place in one or 
both cells such that A's efficiency, as one of the cells firing B, is increased”  
                     (Hebb, 1949)  
Thus, Donald O. Hebb was one of the first people to describe activity-
dependent neural plasticity.  
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The neural basis, underlying memory formation, is proposed to be due to 
changes in synaptic strength, i.e. long-term potentiation (LTP)  (Bliss and 
Collingridge, 1993, Bliss and Lomo, 1973, Kandel, 2004). Kandel and co-
workers have contributed tremendously to the understanding of the 
molecular basis for storage of (1) implicit memory by investigation of the 
Aplysia motor and sensory neurons, and (2) explicit memory by studying 
synaptic plasticity of the mammalian hippocampal pyramidal cells (Kandel, 
2004). In mammals, LTP has been most extensively studied in the 
hippocampal pyramidal neurons known to be essential for the encoding of 
explicit memories, e.g. spatial memory (Kandel, 1999). 
Glutamate and memory  
The hippocampal pyramidal cells, known as “place cells”, are essential for 
spatial learning and memory since these cells encode extra-personal space 
(O'Keefe, 1979). Spatial learning is dependent upon NMDAR functioning 
in the hippocampus. Treatment with NMDAR antagonists block both 
spatial memory and hippocampal place cell LTP, in rodents (Morris, 1989, 
Morris et al., 1986). Studies of spatial learning and memory in rodents, are 
some of the most well established ways of studying explicit memory in 
experimental animals (Morris, 1984, Smith and Mizumori, 2006). 
 
The process of LTP can be divided into early phase LTP (E-LTP) and late 
phase LTP (L-LTP) (Frey et al., 1993, Nguyen et al., 1994). E-LTP is the 
initial synaptic facilitation, lasting 1 to 3 hours, thought to underlie short-
term memory. E-LTP is induced by increased presynaptic glutamate 
release stimulating postsynaptic influx of Ca2+ through NMDARs, 
resulting in phosphorylation and insertion of AMPARs into the synapse. 
Thus, E-LTP does not require de novo protein synthesis (Malenka and 
Nicoll, 1997, Frey et al., 1993).  
 
By contrast, L-LTP lasts up to days, and occurs when there is a stronger 
facilitation of the synapse such that the postsynaptic intracellular Ca2+ 
levels are high enough, or facilitated by a modulatory DAergic input, to 
activate cAMP. The cAMP activation in turn activates a cascade of kinases 
and transcription factors resulting in de novo protein synthesis of e.g. 
growth factor brain-derived neurothrophic factor (Nguyen et al., 1994, 
Frey et al., 1993, Huang and Kandel, 1995, Kovalchuk et al., 2002). In the 
hippocampus, NMDARs can induce LTP, however, their activity is tightly 
regulated by D1/D5Rs (Huang and Kandel, 1995), AMPARs, and 
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GABARs (as reviewed in Collingridge et al., 2004). Furthermore, NO may 
act as a retrograde messenger during both the early phase E-LTP and L- 
LTP (Lu et al., 1999, O'Dell et al., 1991, Zhuo et al., 1994). 
Memory in schizophrenia  
Patients with schizophrenia display deficits in several different explicit 
memory domains (Gold et al., 1992), such as verbal memory (Toulopoulou 
et al., 2003, Hill et al., 2004), spatial memory (Fleming et al., 1997, Hanlon 
et al., 2006), and episodic memory (Clare et al., 1993, Rushe et al., 1999). 
Furthermore, this patient group has a fundamental disruption of working 
memory and executive functioning, mediated by the PFC (Bertolino et al., 
2006, Gold et al., 1997, Goldman-Rakic et al., 2004). Hippocampal 
abnormalities, governed by glutamatergic and acetylcholinergic imbalance, 
are consistently found in patients with schizophrenia (Freedman et al., 
2000, Lahti et al., 1995, Tamminga, 2006) and such abnormalities are 
further associated with declarative memory deficits (Preston et al., 2005). 
Among the working memory deficits are e.g. problems with spatial working 
memory (Park and Holzman, 1992, Piskulic et al., 2007). Deficient working 
memory is attributed to an imbalance in GABAergic, glutamatergic and 
DAergic interactions of the PFC (Lewis and Moghaddam, 2006, Castner 
and Williams, 2007). Thus, there are fundamental memory deficits present 
in patients with schizophrenia and these deficits determine both functional 
outcome and treatment response (Green, 1996, Green, 2006).  
Social cognition 
Increasing attention has recently been paid to social cognition deficits in 
patients with schizophrenia (Bertrand et al., 2007, Burns, 2006a, Green et 
al., 2005). Traditionally, social withdrawal in schizophrenia has been 
considered a negative symptom. Lately however, there has been a focus on 
elucidating the underlying cognitive dysfunctions as they e.g. predict 
functional outcome (Couture et al., 2006, Green et al., 2005). Social 
cognitive deficits include low social cue recognition, impaired facial 
recognition as well as problems with theory of mind (Hall et al., 2004, 
Sprong et al., 2007, Zhu et al., 2007). In summary, dysfunctions in social 
cognition include several domains, such as memory impairments, affective 
disturbances, and executive functional deficits in patients with 
schizophrenia. For further discussion see “Social cognition in 
schizophrenia: The road ahead”, page 59. 
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Treatment 
With the revolution of chlorpromazine in the 1950´s came the 
introduction of the first generation antipsychotics. First generation 
antipsychotics are characterized by high D2R affinity, occupying 
approximately 65-89% of D2Rs, in clinically effective doses (Farde et al., 
1988). This treatment alleviates the psychotic positive symptoms very well. 
However, the high D2R affinity results in aversive side effects including 
extrapyramidal side effects. The second generation antipsychotics were 
developed in the 1970´s and display a D2R occupancy of 40-65% (Farde et 
al., 1989). The second generation antipsychotics induce less DA-dependent 
side effects than the first generation antipsychotics. The “prototype” of 
second generation antipsychotic is clozapine. In addition to its D2R 
antagonist activity, it also has affinity for the serotonin (5-HT)2A receptor 
(5-HT2AR), the histamine type-1 receptor, adrenergic type-1 receptor, and 
the muscarinic type-1 receptor  (Capuano et al., 2002). Although inducing 
less extrapyramidal side effects than most of the effective second 
generation compounds, clozapine treatment can lead to agranulocytosis, 
diabetes, and obesity (Schultz and Andreasen, 1999). Besides improving 
positive symptoms, second generation antipsychotics have been reported 
to have some, although modest, beneficial effects on negative symptoms 
and cognitive deficits (Murphy et al., 2006). The most recently developed 
approved antipsychotic treatment is the DA-stabilizer, i.e. the third 
generation antipsychotic, aripiprazole. Aripiprazole is a partial DA agonist, 
proposed to primarily stabilize the striatal-cortical DA-dysregulation 
underlying schizophrenia (Carlsson et al., 2004, Nilsson et al., 2004).  
 
Until recently, all antipsychotics have displayed DA affinity. However, a 
recent phase-2 trial showed that mGlu receptor 2 and 3 (mGluR2/3) 
agonists, LY2140023, have clinical efficacy comparable to olanzapine. 
LY2140023 treatment was found to significantly improve schizophrenia 
symptoms in comparison to controls (Patil et al., 2007).  Metabotropic 
glutamate agonists of this kind exert their effects on the limbic system by 
decreasing presynaptic release of glutamate (Schoepp, 2001).  
 
Another approach in targeting the glutamate system is to use NMDAR 
partial agonists, glycine, D-serine, and D-cycloserine. These modulators 
have been investigated as adjunctive treatments in schizophrenia with 
variable results. Clinical trials of these agonists show that D-serine, as an 
additive treatment, has the most beneficial effect in alleviating otherwise 
treatment-refractory schizophrenia (Heresco-Levy et al., 2005). 
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Furthermore, other trials have shown that sarcosine, a glycine transporter 
inhibitor, is effective as an add-on therapy to antipsychotic treatment (Tsai 
et al., 2004, Heresco-Levy, 2006).  
 
Taken together there are some new promising drug candidates for treating 
schizophrenia on the rise. Moreover, perhaps in the future we will have the 
option of designing more symptom specific treatment regimens for 
schizophrenia. 
The phencyclidine model 
The PCP model of schizophrenia emerged in the 1950´s as the anaesthetic 
compound, Sernyl®, was tried in healthy volunteers. PCP induced a 
psychosis-like state in healthy volunteers, including sensory perceptive 
delusions, affective changes, stereotypies and cognitive deficits. PCP was 
therefore described as a “schizophrenomimetic drug” (Allen and Young, 
1978, Luby et al., 1959, Yesavage and Freman, 1978). When PCP was 
given in a single dose to patients with schizophrenia, their symptoms were 
exacerbated up to several weeks, compared to healthy controls in which 
the drug effects wore off in a matter of hours (Luby et al., 1959). In the 
1960´s PCP, or “angel dust”, became a drug of abuse where by a one time 
exposure to the drug could induced psychotic states. Repeated use of PCP 
could cause a more persistent drug-induced psychotic state (Rainey and 
Crowder, 1975). PCP has since been used to model aspects of 
schizophrenia in experimental animals. Although PCP is no longer used to 
mimic schizophrenia in humans, ketamine is used for this purpose (Krystal 
et al., 1994). Ketamine, as well as PCP, works by decreasing NMDAR-
mediated neurotransmission, and although less potent, displays a similar 
receptor profile to PCP (Kapur and Seeman, 2002).  
 
The main pharmacological property of PCP is non-competitive 
antagonism of the NMDAR. However, PCP also has affinity for e.g. the 
D2R, the 5-HT2R, the sigma receptor, as well as potassium channels 
(Rothman, 1994, Kapur and Seeman, 2002). Furthermore, acute 
administration of PCP leads to increased DA release in rats (Hertel et al., 
1995, Jentsch et al., 1997a), while subchronic PCP-treatment decrease DA 
release in monkey and rat PFC (Jentsch et al., 1998, Jentsch et al., 1997b). 
Thus, PCP administration leads to an imbalance in the prefrontal DA 
system in accordance with the pathophysiology of schizophrenia (as 
reviewed in Jentsch et al., 1997b and Jentsch, 1999). Long-term PCP abuse 
leads to decreased frontal blood flow (Hertzmann et al., 1990, Wu et al., 
1991), which is in alignment with clinical findings of “hypofrontality, that 
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is further associated with cognitive deficits in schizophrenia (Goldman-
Rakic, 1990, Ingvar and Franzen, 1974, Weinberger et al., 1986). Acute 
PCP administration causes an increase in glutamate overflow in the PFC 
(Adams and Moghaddam, 1998, Takahata and Moghaddam, 2003) as well 
as increased cerebral blood flow in the basal ganglia, thalamus, 
hippocampus and PFC in the rat (Gozzi et al., 2007). Such abnormalities 
most likely contribute to the disruption of cognitive functions observed 
after acute PCP administration (Jentsch, 1999).  
 
In experimental animals, PCP is used to model a NMDAR 
hypofunctioning and produce deficits in several translational behavioural 
animal models for schizophrenia, such as locomotor activity, social 
interaction, sensory information processing, selective attention and 
working memory (Adams and Moghaddam, 1998, Egerton et al., 2005, 
Geyer et al., 1984, Javitt, 2007, Jentsch and Anzivino, 2004, Klamer, 2004, 
Ogren and Goldstein, 1994, Palsson et al., 2005, Sams-Dodd, 1995). Thus, 
the PCP-model mimics aspects of behavioural and neurophysiological 
deficits observed in schizophrenia.  
Phencyclidine-induced behavioural deficits: Role of nitric 
oxide 
Some of the behavioural effects of PCP can be blocked by second 
generation antipsychotics (Fejgin et al., 2007b, Hashimoto et al., 2005b, 
Johansson et al., 1994). The PCP model is proposed to display heuristic 
potential to identify new treatment targets against cognitive deficits 
observed in patients with schizophrenia (Lipska and Weinberger, 2000). 
However, available antipsychotics lack the ability to fully improve the 
cognitive dysfunctions and hence the need for novel cognitive enhancing 
treatments. One potentially new treatment target may be the NO signalling 
pathway. Previous animal studies from our research group have shown 
that PCP-induced disruption of several translational behaviours, on 
different levels of cognitive demand, can be blocked by pretreatment with 
a NOS inhibitor. These translational behaviours include hyperlocomotion, 
decreased prepulse inhibition of acoustic startle, low response habituation 
of acoustic startle, and abnormal latent inhibition, Figure 5. These findings 
suggest a potentially new treatment approach of particularly interest, since 
there is accumulating clinical evidence for involvement of NO in the 
pathophysiology of schizophrenia (Bernstein et al., 2005, Palsson, 2006).  
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Figure 5: On the left are cognitions behaviours deficient in schizophrenia and on the right 
are the translational animal models used to measure these cognitive functions. Acute PCP 
treatment disrupts all the behaviours displayed in the figure. Furthermore, the PCP-induced 
deficits are ameliorated by NOS-inhibition (Johansson et al., 1997, Klamer et al., 2001, 
Klamer et al., 2004c, Klamer et al., 2004d, Klamer et al., 2005a, Klamer et al., 2005b). 
 
NO production is regulated by three different isoenzymes of NOS (for 
further information see ”Nitric oxide and schizophrenia”, page 18). 
Previous studies from our research group suggest that the neuronal version 
of NOS is mediating the PCP-induced behaviours. As such, PCP-induced 
disruption of both PPI and locomotor activity was normalized in rats and 
mice by a selective nNOS inhibitor (Johansson et al., 1999, Johansson et 
al., 1997, Klamer et al., 2004b). Furthermore, mice lacking the nNOS 
isoenzyme did not display PCP-induced hyperlocomotion (Bird et al., 
2001).  We thus hypothesize that PCP-induced deficits ameliorated by 
NOS-inihibition are mediated via nNOS.  
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Phencyclidine-induced behavioural deficits: What can we 
expect from animal models? 
Extensive schizophrenia research has provided us with increasing 
knowledge regarding this complex disorder. However, the aetiological 
factors and underlying pathophysiology still remains unknown. The 
complex diversity in the clinical picture of schizophrenia probably 
pinpoints the many different mechanisms resulting in its characteristic 
symptoms. Several different animal models have been proposed to model 
schizophrenia, including neurodevelopmental lesions and pharmacological 
models, social isolation paradigms, and acute pharmacological 
psychotomimetic interventions (Carlsson et al., 2004, Geyer et al., 1993, 
Javitt, 2007, Lipska, 2004). Still, no single existing animal model has so far 
proved to fully mimic schizophrenia.  
 
Given the heterogeneity of the schizophrenic disorder and its unknown 
aetiology, it is currently highly unlikely to find an animal model that 
completely mimics the disorder in all its regards. However, optimally 
animal models of psychiatric disorders should be evaluated according to its 
face, construct, and predictive validity as a schizophrenia model.  
 
Animal models of psychiatric disorders can be classified as having 
construct, face or predictive validity (Willner, 1984): 
 
  Construct validity similar underlying neurophysiological concept 
  Face validity  similar endpoint measurements in clinical  
 and experimental models 
  Predictive validity        similar pharmacological profile in clinical  
 and experimental studies 
 
The PCP model of schizophrenia displays high face validity as PCP 
induces the same type of behavioural deficits as observed in schizophrenia, 
both in humans and in experimental animal (Figure 5, Javitt, 2007, Jentsch,  
1999). PCP mimics some of the aberrant neurochemical findings of 
schizophrenia such as e.g. hyperDAergia (for more information see “The 
phencyclidine model”, page 28). Since schizophrenia seems to be a 
neurodevelopmental disorder, acute pharmacological manipulations will 
not fully mimic the disorder. In spite of this limitation, PCP mimics some 
of the symptoms of schizophrenia, and can thus be used to model certain 
schizophrenia-like features.  
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AIM OF THESIS  
The overall purpose of this research was to investigate the role of NO-
signalling as a potential new treatment target to eliminate cognitive deficits 
in schizophrenia. In this thesis the role of NOS-inhibition on PCP-induced 
deficits in higher order cognitive functions and social behaviour, was 
studied in animal models.  
Specific aims 
I. To investigate the NO-dependent effects of PCP on spatial 
learning, working memory, long-term memory, and cognitive 
flexibility using different versions of the Morris water maze 
(MWM). 
 
II. To elucidate the NO-dependent effects of PCP on social 
interaction and recognition memory. 
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MATERIALS AND METHODS 
Animals 
In all the experiments, male Sprague-Dawley rats with a body weight of 
250 grams were purchased from B&K Universal AB, Sollentuna, Sweden. 
Upon arrival to the animal facility the animals were housed in cages 
(Macrolon IV, 24 x 42 x 15 cm) of maximum four animals per cage. The 
rats were housed in a colony room for one to two weeks before testing 
started in order to habituate. Food (Harlan Teklad, Norfolk, England) and 
tap water was available ad libitum, room temperature (20 ± 1˚ C) and 
humidity (55%) was kept constant. The daylight cycle was maintained 
artificially, lights went off at 18:00 till 7:00 h and experiments were 
performed during the light phase. The studies were all approved by the 
Ethics Committee for Animal Experiments, Göteborg, Sweden. 
Drugs 
Drugs used were phencyclidine (1-(1-phenylcyclohexyl)piperdine HCL, 
PCP) (RBI, Natick, USA) and NG-nitro-L-arginine methyl ester (L-
NAME) (RBI, Natick, USA). Both PCP and L-NAME were dissolved in 
saline (0.9% NaCl dissolved in distilled water) and injected in a volume of 
2 ml/kg subcutaneously (sc). Saline (SAL) was used as vehicle.  In all 
experiments L-NAME was injected 10 minutes prior to PCP, and 25 
minutes before behavioural testing began (i.e. before the first swim of each 
training day and before the social interaction test on day 1). The doses 
were selected based previous findings within the research group 
(Johansson et al., 1997, Klamer et al., 2005a) 
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Behavioural models 
Apparatus 
Morris water maze 
A circular pool with a diameter of 1.4 m and a circular Plexiglas platform 
(HVS Image, UK) with a diameter of 10 cm was used. The pool was filled 
with water of a temperature of 24± 1° C and the water surface was kept 2 
cm above the platform. Water soluble paint (Allmogefarg, Panduro, 
Göteborg, Sweden) was used to make the water opaque. The pool was 
placed in a room with external cues (geometric black shapes on white 
background), mounted on the walls. These cues were kept in a constant 
position throughout the whole experiment (Figure 6). A camera mounted 
in the ceiling recorded the behaviour using the 2020 Plus Tracking System 
(HVS Image, UK).               
 
 
 Figure 6: Schematic drawing of the MWM setup.  
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Social interaction 
The social interaction test was carried out in eight sound attenuated 
locomotor activity boxes (70x70x40cm, Plexiglas, Kungsbacka mät- och 
reglerteknik AB, Fjärås, Sweden). Locomotor activity was assessed by the 
number of crossings of eight by eight photocell beams directed across the 
floor of the box. Animal behaviour was also recorded by a video camera 
(Canon MV900). The luminescence inside the box was set to 3.5-7 lux. 
The boxes were carefully cleaned between test sessions to minimise 
distracting odours. 
Experimental procedure 
Morris water maze 
The MWM paradigm was first established by Richard Morris in the 1980´s 
and has since been consistently used to assess rodent spatial memory 
(Morris, 1984). A novel paradigm of the MWM that allowed the estimation 
of both spatial learning, working memory, and long-term memory (i.e. 
reference memory), on each of the acquisition days, was developed by 
Baldi and co-workers (2005).  In Paper I, the original MWM paradigm was 
applied and in Paper II, the Baldi paradigm was used. Paper III was based 
on a combination of the Baldi paradigm and a version of the MWM in 
which platform positions were varied between days (Steele and Morris, 
1999). 
 
In all water maze experiments animals were given an acclimatization 
session two days before the acquisition period started. During the 
acclimatization session each rat was allowed 30 s to swim around in the 
maze without the platform present. Depending on what type of memory 
that was investigated, the paradigms varied between the different 
experiments. The different experimental procedures are summarized in 
Table 2. In all experiments each acquisition session consisted of five or ten 
consecutive swimmings for four to five consecutive days. During 
acquisition the animal was let into the pool from one of eight positions (N, 
E, SE, S, SW, W, NW, NE), facing the wall of the pool. The platform was 
always held in a constant position within days, but varied between days in 
Paper III. During acquisition sessions, mean time to find the platform (s) 
of all trials in one day and swim speed (m/s) were recorded. When an 
animal located the platform, or was guided to it (this occurred when the 
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platform was not located within the limited search period), the animal was 
allowed a platform rest before the next swimming started.  
 
Probe trials were executed in order to measure memory of the previous 
platform position. During probe trials the platform was removed and the 
animals memory for the previous platform position was assessed during a 
60 s swimming trial. Memory for the previous platform position was 
measured as either; % of time spent in the quadrant of the pool where the 
platform had previously been located (i.e. the target quadrant) or, by 
assessing mean distance (m) to the previous platform position. After each 
swimming session the animal was washed and allowed to dry under a fan 
heater before put back into the home cage. 
 
PAPER   ACQUISITION  PROBE    
  Days 
# of 
Swimm-
ings/day 
Swimm-
ing 
length (s) 
Platform 
position 
Plat-
form 
rest (s) Days 
# of 
trials/
day 
Length 
of trial 
I: exp 1 1- 4 5 90 constant 30 7 2 60 
I: exp 2 1- 4 5 90 constant 30 7 1 60 
II 1- 5 10 60 constant 20 1 to 5 2 60 
III 1- 4 10 60 varied bw days 20 1 to 5 2 60 
 
Table 2: Summary of experimental procedure for Papers I, II, and III. Category for “Days” 
 imply days over a period of 7 consecutive days (Day 1 to 7) (bw= between). 
Paper I 
In the first two experiments, of Paper I, the design was arranged in order 
to study spatial learning and long-term (i.e. reference) memory in the water 
maze. 
 
Dose-dependent effects of PCP  
In experiment 1 the effect of PCP dose was evaluated as rats were injected 
with PCP in a dose of 0.5, 1.0 or 2.0 mg/kg or SAL (n=10), 15 min prior 
to the first swim on each of the four acquisition days. The platform was 
kept in the NE quadrant throughout the whole acquisition period. After 
the last day of acquisition the animals were allowed to rest for two days 
and then on the third day they went through a drug-free probe test. During 
probe trials the % of time spent in the target quadrant was measured over 
the 60 s period. 
 
State-dependency effects  
After the initial probe test in experiment 1, the state dependent effects of 
PCP were evaluated as the rats, right after the initial probe test were 
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injected with the same dose of PCP (2 mg/kg, n=10) as during acquisition 
and then allowed to swim in the pool for another 60 s, platform removed. 
The second probe trial was done in order to control for state dependency 
effects on search behaviour for the platform and the % of time spent in 
the target quadrant was assessed. 
 
Effects of L-NAME on PCP-induced deficits 
In experiment 2, the effect of pretreatment with L-NAME on the PCP-
induced effects was investigated. On each of the acquisition days the rats 
were pretreated with L-NAME (10 mg/kg) or SAL prior to the PCP (2 
mg/kg) or SAL injection. The platform was maintained in the SW 
quadrant throughout the acquisition period. The probe trial was performed 
in a drug-free state. 
Paper II 
To further investigate NO-dependent effects of PCP on spatial learning, 
working memory, and reference memory, a novel MWM paradigm was 
applied (Baldi et al., 2005). Using this paradigm it was possible to acquire 
more information on each acquisition day than when using the paradigm in 
Paper I. Right before and after each acquisition session there was a probe 
trial on each of the five acquisition days, making it a total of 12 swimming 
trials per day. The first probe trial of each day served to measure what the 
rat remembered from the previous day (i.e. reference memory), while the 
probe trial carried out right after the last acquisition swim of each test day, 
served to assess working memory. Between the acquisition swim and 
probe trials rats were allowed a 20 s platform rest as described above, 
followed by a 20 s cage rest before the next swim trial. This 20 s cage rest 
was carried out in order for the experimenter to eliminate any possible 
odour traces by gently stirring the water or to allow time to put the 
platform back into the water after the probe trial.  
 
On each of the acquisition days the rats were pretreated with L-NAME (10 
mg/kg) or SAL, before the PCP (2 mg/kg) or SAL (n=8) injection. Mean 
distance to platform during the 60 s probe trial (Gallagher proximity 
measure, m) was recorded on each of the five acquisition days. 
Paper III 
The final MWM experiment, of this thesis, was designed to investigate 
higher order cognitive functioning, such as cognitive flexibility and 
executive functioning. Based on a MWM paradigm modified after Steele 
and Morris (1999) we evaluated the effects of PCP and NOS inhibition on 
cognitive flexibility. On each of the acquisition days the rats were 
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pretreated with L-NAME (10 mg/kg) or SAL before the PCP (2 mg/kg) 
or SAL (n=8) injection.. Each swimming session consisted of a total of 11 
swimming trials, the last swim being a probe trial (platform removed).  
Each swimming lasted for a maximum of 60 s followed by a 20 s platform 
rest (except on probe trails) and then a 20 s rest in a plastic cage, followed 
by the subsequent swimming. The platform position was held constant 
within each of the acquisition days but varied between acquisition days, 
such that each animal was to find the platform in a novel position on the 
first swim of each day. During probe trials Gallagher proximity measure 
was assessed. 
Social interaction 
Paper IV 
Two days before the first social interaction test, each animal was 
introduced to the activity box for 10 minutes, one by one, as to habituate 
to the new test environment and thereby eliminate explorative behaviour 
of the environment on the test day. The social interaction test consisted of 
two tests performed on two consecutive days. On the first day, two 
unfamiliar animals were drug-treated with the same treatment and put in 
the same box for 10 minutes. During this 10-minute period, the rats’ 
behaviour was recorded in order to investigate the effects of PCP and L-
NAME on social interaction. Twenty-four hours later the same animals 
were tested according to the same procedure, but without any drug 
treatment, in order to investigate their memory of the social interaction 
from the previous day. On both days of testing, each animal was 
individually put in a plastic cage for 30 minutes before testing began. The 
design of the social interaction test was partly adopted from File and co-
workers (2001) and Sams-Dodd (1995). Social interaction included sniffing, 
licking, following, playing, wrestling, and social supporting (the two rats 
sitting in close proximity, ≤3cm, to each other without interacting). Both 
the frequency (number of interactions) and the time (total time in seconds 
interacting) engaging in social interaction were assessed. Locomotor 
activity was recorded as the total counts of horizontal activity (i.e. number 
of times a photocell beam was interrupted in the horizontal plane). 
 
On the first social interaction test, the rats were pretreated with L-NAME 
(10 mg/kg) or SAL prior to the PCP (2 mg/kg) or SAL injection (i.e. the 
main treatment). Five pairs of rats in each of the four treatment groups 
(SAL+SAL, SAL+PCP, L-NAME+SAL, L-NAME+PCP, n=10) were 
used. 
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Statistics 
Paper I 
The acquisition sessions were analysed using a repeated measures two-way 
ANOVA with treatment as between-subjects factor and trial as within-
subjects factor followed by Bonferroni’s Multiple Comparison Test.  
 
Analysis of probe trials were done separately using a one-way ANOVA 
with treatment as between-subjects factor followed by Dunnett’s Multiple 
Comparison Test. One sample t-tests were used to separately analyse 
preference for the target quadrant and state dependent effects related to 
drug treatment.  
Paper II 
The acquisition trials were analysed using a repeated measures two-way 
ANOVA with treatment as between-subjects factor and acquisition session 
as within-subjects factor, followed by Bonferroni’s Multiple Comparison 
Test. Analysis of probe trials was carried out separately using a two-way 
ANOVA with treatment as between-subjects factor and the trial as within-
subjects factor, followed by Bonferroni’s Multiple Comparison Test. 
Paper III 
In Paper III, acquisition trials were analysed using a repeated measures 
three-way ANOVA with pretreatment (SAL or L-NAME) and treatment 
(SAL or PCP) as between-subjects factors and acquisition session as 
within-subjects factor. Post hoc analysis was performed by Bonferroni’s 
Multiple Comparison Test when appropriate.  
Paper IV 
Two- or three-way ANOVA followed by Tukey´s HSD test for 
comparison between treatment groups were used to analyse the 
experimental data.  Two-way ANOVA using pretreatment (SAL or L-
NAME) and treatment (SAL or PCP) as between-subjects factors assessed 
drug effects on time in social interaction, number of interactions and 
locomotor activity on test-Day 1. Three-way ANOVA was used to evaluate 
treatment effects on social interaction using pretreatment (SAL or L-
NAME) and treatment (SAL or PCP) as between-subjects factors, and test 
day as within-subjects factor (test-Day 1 and 2). 
 
Two-tailed levels of significance were used in all the above mentioned 
analyses and P<0.05 was considered statistically significant.  
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RESULTS AND DISCUSSION 
Paper I: Effects of phencyclidine on spatial learning and 
memory: Nitric oxide-dependent mechanisms.  
Cognitive deficits of schizophrenia are predictive of disease outcome as 
well as functional level and are not alleviated by antipsychotic treatment 
(Green, 2006, Green, 1996). Therefore, methods for studying cognitive 
deficits with relevance for schizophrenia are needed in order to find better 
pharmacological treatments. Previous findings within the research group 
show that PCP-induced deficits in sensory information processing, i.e. 
prepulse inhibition, habituation of acoustic startle and selective attention, 
can be ameliorated by NOS-inhibition (Klamer et al., 2004b, Klamer et al., 
2004d, Johansson et al., 1997). Based on these findings, the present study 
was carried out in order to evaluate the NO-dependent effects of PCP on 
higher order cognitive functions, such as spatial learning and reference 
memory, i.e. spatial long-term memory, using the MWM paradigm as 
adopted from Morris (1984).        
 
The dose-response experiment showed that PCP (2 mg/kg) disrupted (i.e. 
delayed) spatial learning as indicated by significantly increased time to find 
the platform over the four training days. Furthermore, PCP administration 
also impaired reference memory as displayed by significantly less amount 
of time spent in the target quadrant compared to controls. The time to find 
the platform in rats treated with the lower doses of PCP (0.5 and 1.0 
mg/kg) did not differ from control animals. Therefore PCP 2 mg/kg was 
chosen as the appropriate dose to use, which was in accordance with 
previous studies by our research group (Klamer et al., 2005b, Klamer et al., 
2005a, Johansson et al., 1997, Palsson et al., 2005). No state-dependent 
effects of PCP were detected on time spent searching for the platform 
during probe test. This indicates that PCP does not function as a cue to 
initiate search for the platform in rats that were treated with PCP during 
acquisition. Moreover, control animals displayed a significant decrease of 
searching behaviour in the target quadrant on the second probe test. The 
behaviour of the control animals implicates learning that the platform is 
not in the previous position, in only one probe trial.  
 
Surprisingly, in the first experiment, PCP (2 mg/kg), delayed spatial 
learning significantly during the first two days of acquisition. However, on 
the third and fourth day there was no difference in time to find the 
platform between treatment groups. In experiment two, PCP-treatment 
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not only delayed but also impaired spatial learning significantly over the 
whole four-day acquisition period.  The explanation for this discrepancy 
remains unknown. A possible explanation could be that the discrepancy is 
due to differences in batches of animals, or to the increased experience of 
the researcher carrying out the second experiment.  
 
Furthermore, in experiment two, pretreatment with the NOS inhibitor, L-
NAME, completely restored the PCP-induced spatial learning deficit, 
however did not manage to restore the reference memory dysfunction as 
measured on the probe test, Figure 7. The lack of restoration of the PCP-
induced reference memory deficit was surprising given that rats treated 
with L-NAME+PCP seemed to have learned the position of the platform 
as well as control animals during acquisition, and therefore were expected 
to remember the platform position equally well on probe test.  These 
effects indicate that some PCP-induced deficits of spatial learning and 
memory are NO-dependent, while others are not (Knepper and Kurylo, 
1998, Kesner et al., 1993). PCP, besides being a NMDAR antagonist, also 
display affinity for the 5-HT2R, the sigma receptor and the D2R. 
Consequently it is possible that some of the effects of PCP on these 
receptors may contribute to some of its NO-independent effects (Kapur 
and Seeman, 2002). 
 
Figure 7: Left: The effects of PCP and L-NAME on acquisition of a spatial learning task 
using the MWM (♦♦p<0.01). Right: The effects of L-NAME (NAM) and PCP on long-
term memory.  p<0.01 and  p<0.05 compared to saline (SAL)-treated rats, ♦♦♦ 
p<0.001 and ♦ p<0.05 vs. 25% time spent in the target quadrant. For details see Paper I. 
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Interestingly, patients with schizophrenia display the same type of deficits 
in a virtual version of the MWM (Hanlon et al., 2006), as observed in 
Paper I. Thus, patients with schizophrenia showed a delayed time to find 
the platform during acquisition and less time spent in the target quadrant 
during probe test. This indicates high face validity for our experimental 
animal model for spatial learning and memory in schizophrenia.  
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Paper II: Phencyclidine affects memory in a nitric oxide-
dependent manner: Working and reference memory. 
Patients with schizophrenia consistently display deficits in different types 
of working memory, such as spatial working memory (Carter et al., 1996, 
Park and Holzman, 1992). These spatial working memory deficits can be 
attenuated by some second generation antipsychotics (i.e. risperidone) but 
worsened by others, such as clozapine (McGurk et al., 2005). Hence these 
deficits are not consistently alleviated by available antipsychotic treatments 
and therefore new pharmacological tools are needed. Based on the findings 
from Paper I, we wanted to further investigate the effects of NOS-
inhibition on PCP-induced deficits on working- and reference memory. 
 
The paradigm used in this paper tested spatial learning, working memory, 
and reference memory within the same session, on each of the five 
acquisition days. In this way a continuous measure of these different 
aspects of memory over the whole testing period was obtained. The results 
from Paper II show that PCP disrupts spatial learning as PCP-treated 
animals took significantly longer time to find the platform on each of the 
five acquisition days. The probe test carried out right after the last 
acquisition trial of each day assessed working memory. PCP treatment 
disrupted working memory as these rats showed a significantly longer 
mean distance to the previous platform position (i.e. a higher 
Gallaghers´proximity index), compared to control rats. Reference memory 
was measured on the first probe test of each acquisition day. PCP-treated 
animals showed significant reference memory deficits compared to 
controls. On Day 1, all animals displayed the same results on the reference 
memory test. This indicates that PCP had no motor side effects that 
disrupted the behaviour required for probe testing (Figure 8). Thus, PCP 
had no effects on probe test behaviour before any learning had occurred 
on Day 1. This further strengthens the treatment effects on learning and 
memory on the following acquisition days. 
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Figure 8: The effect of PCP and L-NAME on reference memory using the MWM. 
 p<0.01,  p<0.001 compared to SAL-treated rats. For details see Paper 
II. 
 
The results further demonstrate that blocking the synthesis of NO, by 
pretreatment with L-NAME completely restored the PCP-induced deficits 
on spatial learning, working memory, and reference memory to control 
levels. L-NAME, by itself, had no effects on any of the measured 
behaviours.  
 
Analysis of swim speed showed that there was a significant effect of PCP 
on this measure during acquisition training such that PCP-treated animals 
swam faster than all other treatment groups. This finding is probably due 
to induction of thigmotaxis (aimless forward-only swimming along the 
edges of the pool, for example see Figure 10) in PCP-treated animals. 
Interestingly, this increase in swim speed was normalized by L-NAME 
pretreatment.  In line with these findings, we have previously shown that 
also PCP-induced locomotor stimulation can be blocked by NOS-
inhibition (Johansson, 1997). Hyperlocomotion has been linked to 
increased DA efflux in the nucleus accumbens (Engel and Carlsson, 1977). 
However, PCP-induced hyperlocomotion was not found to be temporally 
associated with DA overflow in the rat nucleus accumbens whereas such 
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an association between glutamate efflux in the rat nucleus accumbens and 
hyperlocomotion was obtained (Adams and Moghaddam, 1998). 
Moreover, in our own studies PCP-induced increase in DA overflow in the 
rat nucleus accumbens was significantly ameliorated by L-NAME 
preteratment. Amphetamine-induced hyperlocomotion and DA overflow 
in the rat nucleus accumbens on the other hand, was not affected by L-
NAME pretreatment (Johansson, 1998). Thus, the NO-dependent effects 
of PCP on locomotor activity may primarily be related to changes in 
glutamate function.  
 
Taken together, the results from Paper II show that PCP induces deficits 
in several learning and memory domains consistently found to be impaired 
in patients with schizophrenia. Moreover, all these PCP-induced memory 
impairments were attenuated by interfering with NO production. In sum, 
there seems to be a NO-dependent mechanism underlying PCP-induced 
disruption of spatial learning and memory. 
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Paper III: Effects of phencyclidine on cognitive load: 
Targeting the nitric oxide system.  
Functions dependent on the PFC, such as working memory, executive 
functioning, and planning are often impaired in patients with 
schizophrenia (Castner et al., 2004, Gold et al., 1997, Semkovska et al., 
2004). Lack of these functions may lead to cognitive stereotypy 
(perseveration or lack of cognitive flexibility) observed in schizophrenia (as 
reviewed in Drake and Lewis, 2003). In Paper III, we wanted to investigate 
the effects of PCP and NOS inhibition on cognitive functioning 
dependent upon the PFC, i.e. cognitive flexibility.   
 
In order to investigate cognitive flexibility we used a paradigm that 
required the rat to deal with a new situation of the same task, each testing 
day. The idea here was that rats would have to develop an efficient search 
strategy trying to find the new platform position between days. 
 
The results showed that control animals displayed a significantly decrease 
in time to find the platform Day 1 compared to Day 2 and 3. However, on 
the fourth day, as the platform was moved a fourth time, the animals 
showed an increase in time to find the platform, Figure 9. Thus, one 
advantage with this model is that it estimates the limits of the rats’ 
cognitive ability. 
 
PCP treatment disrupted learning on the three first days of testing 
compared to all other treatment groups. Furthermore, excluding the PCP 
group there was no significant difference between any of the other 
treatment groups. Thus, pretreatment with L-NAME normalized the PCP-
induced inability to learn to find the platform.  
 
Analysis of swim speed showed no significant effects of treatment and 
analysis of probe trials showed no significant treatment or training effect. 
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Figure 9: The effect of PCP and L-NAME on acquisition during a “constant spatial 
reversal” using the MWM. PCP impaired acquisition (??p< 0.01). L-NAME 
pretreatment normalized the PCP-induced deficits. For details see Paper III. 
 
The swimming pattern diagram is a representative drawing of how PCP 
and/or L-NAME treatment affects search strategy, Figure 10. The 
illustration present swim patterns of ten consecutive swimming trials from 
one animal on Day 2. The diagram indicates that the PCP-treated rat show 
pronounced thigmotaxis (swimming along the edges of the pool) and a 
chaotic pattern indicating aimless swimming. Interestingly, animals 
pretreated with L-NAME, before PCP, displayed a swimming pattern that 
very much looked like the control rats´ as these rats found the platform on 
a majority of the trials. 
 48 
 PCP 
 
L-NAME+PCP L-NAME 
CONTROL 
 
 
Figure 10: Swimming pattern diagram. Swimming trails are drawin in white and 
platformposition in black. PCP induced aimless swimming and thigmotaxis. The PCP-
induced impairment was normalized by NOS-inhibition. Fore details see Paper IV.  
 
Taken together, this data could be interpreted as though the control rats 
showed an understanding of the purpose of the task, i.e. finding the escape 
platform, on the first three days of testing. Saline-, L-NAME-, and L-
NAME+PCP-treated animals all demonstrated a significant decrease in 
search time on Day 2 and 3, Figure 9. As the task became more 
demanding, however, the rats did not manage to cope with the task, which 
was displayed by increased time to find platform on Day 4. Based on these 
findings this test does assess the animals´ capacity to learn the purpose of 
the task (i.e. searching for the platform in a new position each day). 
 
In summary, the results from this study show that PCP disrupted the 
searching behaviour as measured by time to find the platform as well as by 
gross observation of the swimming pattern analysis, compared to control 
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animals.  Furthermore, pretreatment with NOS inhibitor, L-NAME, 
restored the PCP-induced disruption in searching behaviour to control 
levels both quantitatively, as measured by time to find the platform, but 
also qualitatively, as observed in swim pattern diagram. Taken together, 
this may be interpreted as though PCP decrease cognitive flexibility, a 
deficit that is normalized by decreasing NO production, in rats.  
 
In conclusion, the results from Paper I, II, and III suggest that PCP-
induced disruption in learning and memory is dependent on NO-signalling. 
This may imply that NO-modulation could be a potential treatment target 
for alleviating learning and memory deficits in schizophrenia. 
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Paper IV: The importance of nitric oxide in social 
dysfunction  
Patients with schizophrenia often suffer from negative symptoms, such as 
anhedonia, avolition and social withdrawal. Negative symptoms are 
chronic in nature and poorly alleviated by available antipsychotics (Stahl 
and Buckley, 2007). Deficits within the social domain are paid increasing 
attention as they are attributed to depend upon an underlying cognitive 
dysfunction (Green et al., 2005). The social interaction model is e.g. used as 
an experimental animal model for studying PCP-induced schizophrenia-
like negative symptoms (Ellenbroek and Cools, 2000, Sams-Dodd, 1999). 
Rats display a pronounced social interactive behaviour that is disrupted by 
PCP, but not amphetamine, indicating that this model is a particularly 
suitable model for evaluating schizophrenia-like negative symptoms 
induced by PCP (Sams-Dodd, 1999). I Paper IV we investigated the effects 
of NOS-inhibition on PCP-induced social interaction deficits, in rats. 
Furthermore, a drug-free memory test was carried out twenty-four hours 
after the initial social interaction test. 
 
The results show that PCP induced deficits in social interaction behaviour, 
by significantly reducing the time spent in social interaction, compared to 
control rats. Pretreatment with a NOS inhibitor, L-NAME, attenuated the 
PCP-induced decrease in time of social interaction to control levels, Figure 
11. Furthermore, no treatment effect on locomotor activity or number of 
social interactions was found, this observation suggests that the PCP-
induced reduction in time of social interaction did not depend on drug-
effects on motor behaviour, e.g. stereotypies.  
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Figure 11: The effects of L-NAME and PCP on social interaction. PCP significantly 
decreased time spent in social interaction (?p<0.05) in comparison to controls. L-NAME 
pretreatment restored the PCP-induced disruption to control levels. For details see Paper 
IV. 
 
Several other studies have evaluated the effects of antipsychotic 
compounds on PCP-induced social interaction deficits, with varying 
results. Sams-Dodd (1997) showed that remoxipride, risperidone, 
sertindole, olanzapine and quetiapine all produced an attenuating effect on  
PCP-induced social interaction deficits. However, all these drugs also had 
an effect on social interaction in control animals. In recent studies, two 
different compounds with both 5-HT1AR receptor agonist and D2R 
antagonistic properties, but not clozapine and haloperidol, reversed PCP-
induced social interaction deficits, in rats (Boulay et al., 2004, Depoortere 
et al., 2007). The attenuating effects were attributed to the 5HTergic 
profile of these compounds. Taken together, there remains uncertainty in 
the literature as to what effects different antipsychotic compounds do have 
on PCP-induced social interaction deficits. The best candidates for 
alleviating such deficits in rats seem to be atypical antipsychotic 
compounds, preferably with some 5-HT1AR affinity. In the clinic, 
available antipsychotic do not fully alleviate the negative symptoms in 
patients with schizophrenia. Thus, this indicates that the PCP-model for 
social interaction may be used as an experimental model for social 
withdrawal. 
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Figure 12: The effect of treatment L-NAME 10 mg/kg (NAM 10), and PCP 2mg/kg (PCP 
2) on time of social interaction test Day 1 (with drug treatment) and Day 2 (no drug 
treatment). There was a significant effect of pretreatment (SAL or L-NAME) and main 
treatment (SAL or PCP) (p<0.01), pretreatment and test day (p<0.05) and main treatment 
and test day (p<0.05).  
 
Our results show that pretreatment with a NOS inhibitor can block PCP-
induced deficits in social interaction. The rats´ social memory of the first 
social interaction (Day 1) was assessed on the second day, Figure 12. These 
results showed that PCP-treated rats increased their time of interaction on 
Day 2, while all other treatment groups decreased their time interacting on 
Day 2, compared to Day 1. These results lack the proper control groups to 
be able to eliminate possible state-dependency effects of PCP on social 
memory. Any interpretation of the data ought therefore to be speculative. 
It is possible that the increase in time of interaction on Day 2 compared to 
Day 1, in PCP-treated rats, was due to a perceived novelty to the other rat, 
as the PCP effect was gone. Rats that spent more time in interaction on 
Day 1 (i.e. SAL+SAL, L-NAME+SAL, L-NAME+PCP- treated rats) did 
decrease their time in interaction on Day 2, thus signalling a decreased 
novelty to the other rat. This decrease in interaction possibly represent 
memory of the interaction from Day 1.  It is however possible that the 
PCP-treated animals did learn to recognize the rat on Day 1, despite less 
time spent in social interaction that day. This might explain why they 
interacted the same amount of time on Day 2 as control animals. The latter 
interpretation could possibly mean that PCP inhibited the executive 
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functioning, or proper motivation, needed to carry out the social 
interaction on Day 1, although learning still occurred.  
 
Taken together the results from Paper IV show that PCP-induced deficits 
in social interaction may be ameliorated effectively by NOS-inhibition, in 
rats. These findings reinforce current notions pertaining to negative 
symptom profiles in schizophrenia and the putative role of NO. 
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GENARAL DISCUSSION 
 
The results presented in this thesis demonstrate that cognitive deficits and 
social dysfunction, studied in experimental animal models of 
schizophrenia, can be ameliorated by interfering with the NO signalling 
system.  
 
PCP disrupts spatial learning, working memory, long-term memory, and 
cognitive flexibility assessed by different versions of the Morris water maze 
paradigm. Using a social interaction paradigm PCP decreased time spent in 
social interaction. Furthermore, all these PCP-induced deficits were 
normalized by pretreatment with a NOS-inhibitor.  
PCP increases production of nitric oxide  
In this thesis we used PCP to model schizophrenia-like deficits in rats. 
PCP exerts its effects by blocking the ion channel of the NMDAR thus 
prohibiting Ca2+ influx. This would in turn decrease intracellular NO 
production since constitutive NOS such as nNOS and eNOS are 
dependent on Ca2+ for their activation. It is therefore controversial that 
blocking NOS, and thus decreasing NO production, would normalize 
PCP-induced deficits. We have in this thesis presented several findings 
indicating that inhibition of the NO production normalized PCP-induced 
deficits in rodents. Therefore we hypothesize that PCP induces an 
increase in NO production in critical brain regions.  
 
Firstly we have, using a microelectrochemical sensor that allows 
measurements of NO levels in living tissue, recently obtained important 
evidence supporting this hypothesis. An increase in NO was demonstrated 
in the PFC and nucleus accumbens in awake, freely moving rats after 
systemic administration of PCP. Furthermore, the increase in NO in the 
PFC was attenuated by pretreatment with L-NAME (Lowry JP et al in 
collaboration, unpublished data).  
 
Further indirect evidence for an activation of NO-dependent signalling 
pathways following acute PCP administration was also recently obtained. 
Thus, a NO-dependent increase in cGMP levels in the mouse PFC was 
shown following acute PCP treatment. As described above (in “Nitric 
oxide an schizophrenia”, page 18), cGMP is the main effector of NO and 
consequently these results imply that the increase in cGMP observed after 
PCP administration is linked to an increase in NO production. It should 
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also be noted that blocking NO-dependent cGMP production with a sGC 
inhibitor locally administered into the mouse PFC normalized PCP-
induced deficits in PPI (Fejgin et al., 2007a).  
 
Another way to interfere with the NO signalling system is to reduce NO 
synthesis by decreasing the availability of L-arginine, the precursor of NO. 
The transportation of L-arginine over the blood brain barrier occurs 
through a cat ionic amino acid transporter (CAT). The same CAT is also 
responsible for transportation of L-lysine. Consequently, L-lysine and L-
arginine compete for the same membrane transporter. In fact, treatment 
with L-lysine has been shown to reduce intracellular stores of L-arginine 
and production of NO in vitro (Carter et al., 2004, Closs et al., 1997). 
Based on these findings we used L-lysine to saturate the CAT in mice and 
found that subchronic treatment with L-lysine reduced PCP-induced 
disruption of PPI (Palsson et al., 2007).  
 
Figure 13: The NO-signalling pathway and the strategies we have used to interfere with the 
pathway (Fejgin et al., 2007, Johansson et al., 1997, Johansson et al., 1999, Klamer at al., 
2004a, Klamer at al., 2004b, Klamer at al., 2004c, Klamer at al., 2005a, Klamer at al., 2005b, 
Lowry JP et al, unpublished data, Palsson et al., 2007, Paper I, II, III, IV). 
 
Taken together, these results imply that acute PCP treatment increases NO 
production in critical regions of the brain.  Furthermore, inhibiting the NO 
signalling cascade on several different levels normalize PCP-induced 
behavioural deficits in a number of translational animal models for 
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schizophrenia (Figure 13). Thus, the NO signalling system may constitute a 
new treatment target for schizophrenia. In order to test our hypothesis 
clinically we are currently setting up a pilot study evaluating the effects of 
adjunctive L-lysine treatment on cognitive deficits and PPI in patients with 
schizophrenia. 
Possible mechanisms of phencyclidine on nitric oxide 
production  
At present, we have accumulated data demonstrating that PCP treatment 
increases levels of NO in the rodent brain. However, the mechanism by 
which this happens remains to be elucidated. On the level of neuronal 
networks, PCP has been demonstrated to alter activity in PFC, 
hippocampus, amygdala, and thalamus. These regions form the cortico-
limbo-thalamic loop, which is considered to make up an important 
network in the pathophysiology of schizophrenia (Gozzi et al., 2007). 
Furthermore, it is hypothesized that a blockade of the NMDAR by PCP 
could result in a complex circuit imbalance as a consequence of 
disinhibition of excitatory pathways which in turn could cause a hyper-
stimulation of primary corticolimbic neurons (Farber, 2003, Olney et al., 
1999, Thornberg and Saklad, 1996).  Even though PCP is generally 
regarded as a NMDAR antagonist it should be emphasized that it also 
interferes with several other neurotransmitter systems, such as the 
noradrenergic, 5-HTergic, DAergic, and GABAergic systems (Etou et al., 
1998, Jones et al., 1987, Yonezawa et al., 1998). Furthermore, PCP has 
affinity for the D2R and the 5-HT2R and it is hence possible that some of 
the NO-related effects of PCP are mediated via direct interactions with 
these receptors (Kapur and Seeman, 2002).  
 
One tentative explanation, provided that the observed effect is 
predominately nNOS mediated, may be as follows. Acute systemic 
administration of a NMDAR antagonist (i.e. PCP) in rodents has proved 
to increase glutamate release accompanied by working memory 
impairments (Abekawa et al., 2006, Moghaddam and Adams, 1998, 
Takahata and Moghaddam, 2003). Although the most well established 
NO-inducing signalling pathway is mediated via glutamate acting on 
NMDARs, there are other glutamate receptors that may contribute to 
Ca2+-dependent NO production. One such receptor candidate may be the 
Ca2+-permeable AMPAR (containing e.g. the GluR1 subunit but not the 
GluR2 subunit) known to regulate long-term synaptic plasticity and 
neurotransmission. These AMPARs are expressed in e.g. the CA1 region of 
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the hippocampus and in GABAergic cortical interneurons (Isaac et al., 
2007, Yin et al., 1994). Furthermore, AMPAR GluR1 subunits have been 
found to co-localize with the NMDAR type 1 subunit and nNOS in rat 
brain (Lin and Talman, 2002). Additional evidence for the involvement of 
AMPARs may be derived from a study showing that PCP-induced 
decrease in electroencephalographic power in the rat PFC is inhibited by 
treatment with an AMPAR antagonist (Sebban et al., 2002). Thus, it is 
possible some of the effects of PCP on NO production may be mediated 
via glutamate acting on these Ca2+-permeable AMPARs. The merit of this 
explanation will need to be tested experimentally, but the very formulation 
of such hypothesis is necessary if the role of NO in the schizophrenia-like 
effects of PCP is to be fully determined.  
 
Taken together, these results suggest that the psychotomimetic properties 
of PCP most likely result from neurochemical alterations encompassing 
several neurotransmitter systems and interacting brain regions. 
 
Proposed clinical relevance 
Accumulating evidence from clinical studies indicate that the NO 
signalling system is involved in the pathophysiology of schizophrenia 
(Bernstein et al., 2005). Genetic studies show associations between several 
NO-associated proteins (e.g. nNOS, tetrahydrobiopterin, synapsin 2) and 
schizophrenia (Reif et al., 2006, Xing et al., 2002, Saviouk et al., 2007, Xu 
et al., 2005, Richardson et al., 2005). Moreover, NO metabolite levels in 
cerebrospinal fluid were found to be decreased while serum NO and post 
mortem NO metabolites and sGC levels were shown to be increased in 
patients with schizophrenia compared to controls (Ramirez et al., 2004, 
Baba et al., 2004, Yilmaz et al., 2007, Yao et al., 2004). These findings 
indicate that there may be a dysregulation of the NO-signalling pathway in 
schizophrenia. This is further supported by a treatment study showing that 
patients with schizophrenia improved their overall psychopathology when 
treated with methylene bleu, a NO/sGC inhibitor (Volke et al., 1999), in 
addition to conventional antipsychotic treatment (Deutsch et al., 1997). 
Interestingly, methylene blue also blocks the PCP-induced disruption of 
PPI in mice (Klamer et al., 2004a).  
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Memory and cognitive flexibility in schizophrenia 
Cognitive deficits are the single strongest predictor of functional outcome 
in patients with schizophrenia (Green, 1996). Among the cognitive deficits 
observed are impairments in long-term spatial memory (Reeder et al., 
2006), spatial working memory deficits (Piskulic et al., 2007), and cognitive 
flexibility (Addington and Addington, 1999). In this thesis spatial learning, 
spatial long-term memory, spatial working memory, and cognitive 
flexibility were studied using different versions of the MWM. Interestingly, 
there is a direct translational correlation between the results from Paper I 
and II and a clinical study in patients with schizophrenia. Using a virtual 
version of the MWM patients displayed longer time to find the platform 
during acquisition and spent less time in the target quadrant during probe 
test compared to controls (Hanlon et al., 2006). These clinical findings are 
in accordance with the results from Paper I and II, since rats treated with 
PCP showed the same type of impairments as the schizophrenic patients.  
 
Spatial learning and memory depends mainly on the hippocampus (Morris 
et al., 1982, Smith and Mizumori, 2006) and blockade of NMDAR impairs 
these cognitive functions (Morris, 1989, Morris et al., 1986). The 
hippocampus has been found to be abnormal in both function and 
structure in patients with schizophrenia (Bogerts et al., 1990, Arnold et al., 
1995, Tamminga et al., 1992). We have recently published evidence from 
our research group that suggests an involvement of hippocampal NO in 
PCP-induced deficits. Results showed a temporal correlation between 
PCP-induced deficits in PPI and increased levels of cAMP in the rat 
ventral hippocampus. These behavioural and neurochemical effects were 
blocked by pretreatment with a NOS-inhibitor, (Klamer et al., 2004c). 
Taken together there are few studies investigating the effects of acute PCP 
administration on NO signalling in the hippocampus.  However, 
conflicting research reports have found that PCP and ketamine induce 
both increased, reduced, and no change in NOS expression in the rodent 
hippocampus (Keilhoff et al., 2004, Miyamoto et al., 2000, Noda et al., 
1996). 
Impairments in working memory are one of the most well established 
cognitive deficits of schizophrenia. Working memory is dependent upon 
the functional integrity of the PFC and several studies have demonstrated 
PFC hypofunctioning in patients with schizophrenia (Callicott et al., 2000, 
Gold et al., 1997, Goldman-Rakic, 1999, Ingvar and Franzen, 1974).  
Working memory is often assessed using the Wisconsin Card Sorting Test, 
a test that also taps into executive function and cognitive flexibility (Shad 
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et al., 2006). It thus becomes difficult to separate these different aspects of 
cognitive functioning and perhaps they are to interdependent to be 
measured independently, even in humans. Regardless of the exact 
relationship between these functions, they are probably unified by the 
dependence upon dorsolateral PFC functioning. In Paper II and III 
working memory and cognitive flexibility were assessed. Although the 
specific role of the PFC was not investigated in these experiments we have 
demonstrated the importance of the PFC for mediating the NO-dependent 
effects of PCP on PPI (Fejgin et al., 2007a) and acute PCP treatment 
increases the production NO in the rat PFC (Lowry JP et al, unpublished 
data). Evaluating the specific role of the rodent PFC in working memory 
and cognitive flexibility by e.g. using a sGC inhibitor would ad further 
information on the role of NO in PFC for cognitive functions.  
 
As mentioned above, cognitive deficits are predictive of functional 
outcome, such as social functioning. However, it is argued that social 
cognitive deficits may constitute a symptom category of their own, 
different from other cognitive deficits observed in schizophrenia (Burns, 
2006a, Lancaster et al., 2003).  Furthermore, cognitive flexibility, working 
memory, and visuo-spatial long-term memory are associated with social 
functioning skills in patients with schizophrenia. On the other hand, 
several cognitive functions implicated in schizophrenia show no 
correlation with social functioning (Addington and Addington, 1999, 
Reeder et al., 2006).  
Social cognition in schizophrenia: The road ahead 
Schizophrenia, despite being a heritable disorder with several clear survival 
disadvantages, still remains within the human population. According to 
Darwinian laws of evolution, schizophrenia should have vanished from the 
population if it was not associated with some advantageous trait. Thus, an 
“evolutionary paradox of schizophrenia” has been proposed as 
schizophrenia survived despite both reduced fecundity and increased 
mortality (Burns, 2006b, Huxley et al., 1964). Such a favourable inherited 
trait could be expressed in individuals carrying some of the heritability for 
schizophrenia without expressing the phenotype. This is the case in first-
degree relatives of patients with schizophrenia, displaying e.g. high 
academic performance (Burns, 2006b, Karlsson, 2004).  
 
The social brain hypothesis states that the evolution of the Homo sapiens 
brain has evolved due to high social selective pressure. Living in a complex 
social environment along with the advantage of forming intense pair bonds 
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have been put forward as the strongest evolutionary forces driving human 
brain evolution (Dunbar and Shultz, 2007). Although a high degree of 
shared genes with primates, humans display specialized social cognitive 
skills, separate from that of our closest primate relatives (Herrmann et al., 
2007).  
 
Social cognition includes functions such as theory of mind (i.e. ability to 
understand other peoples´ beliefs and intentions), social perception, 
emotional processing, and working memory (Burns, 2006a, Green et al., 
2005). The neuroanatomical basis for social cognition includes several 
cortical networks, including the prefrontal, parietal, and temporal 
association cortices (Burns, 2006a). Patients with schizophrenia 
consistently show deficits in several aspects of social cognition that have 
been functionally associated with abnormal activation of e.g. the 
dorsolateral PFC (Russell et al., 2000), the orbitofrontal cortex 
(Sigmundsson et al., 2001), the amygdala, and the hippocampus (Gur et al., 
2002). Thus, schizophrenia is proposed to be a disorder of functional and 
structural connectivity in neuronal networks essential for social cognition 
that remain as a disadvantageous by-product of human brain evolution 
(Burns, 2006b). Given the evolutionary frame of reference, social cognitive 
deficits in schizophrenia might make up a core symptom category of its 
own.  
 
In 1920, Eugene Bleuler wrote that “schizophrenia… is characterized by a specific 
kind of alternation of thinking and feeling, and of the relations with the outer world that 
occur nowhere else”. 
                                (As reviewed in Burns, 2006a) 
 
In accordance with Bleuler, cognitive deficits, and social cognition in 
particular, pinpoints the core features of schizophrenia that still remain the 
greatest treatment challenge today. Perhaps the inability of patients to 
apply an appropriate theory of mind makes them detached from the social 
rules and norms that so strictly govern daily living in the social world for 
most of us. Maybe it is not lack of interest or motivation that fails these 
patients, but the mere lack of a functional prefrontal – temporal 
connection that makes it impossible for them to interpret social cues and 
make inferences based upon them. As discussed above, social cognition 
depends upon an intricate relationship between several functional cognitive 
domains and several brain areas. Available antipsychotics may worsen 
cognition and also induce negative symptoms (Castner et al., 2000, 
Lewander, 1994) and thus further adds to the complexity of this disorder. 
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These side effects, such as anhedonia and lack of drive, may in turn 
enhance the social dysfunction. This complex and intriguing deficit of 
social cognition in schizophrenia, still not affectively treated by 
antipsychotics, needs extensive investigation, as it seems to constitute an 
important core deficit.  
A nitric oxide dysregulation hypothesis for 
schizophrenia 
In summary, the findings of this thesis demonstrate a NO-dependent 
mechanism of PCP-induced cognitive and social dysfunctions. Together 
with previous findings from the research group, we demonstrate that 
NOS-inhibition ameliorates PCP-induced deficits in several translational 
animal models of schizophrenia, ranging from pre-attentive information 
processing to social interaction, Figure 14. 
 
Figure 14: On the left are cognitions/behaviours deficient in schizophrenia and on the right 
are the translational animal models used to measure these cognitive functions. The arrow 
indicates increasing degree of cognitive complexity. Acute PCP treatment disrupts all the 
behaviours displayed in the figure. Furthermore, the PCP-induced deficits are ameliorated 
by NOS-inhibition (Johansson et al., 1997, Klamer et al., 2001, Klamer et al., 2004c, Klamer 
et al., 2004d, Klamer et al., 2005a, Klamer et al., 2005b, Paper I, II, III, and IV).  
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Based on our preclinical findings, together with clinical evidence 
supporting an involvement of the NO signalling system in the 
pathophysiology of schizophrenia, we propose a “NO-dysregulation 
hypothesis for schizophrenia”. Available antipsychotics are doubtlessly 
important for managing psychosis. Although second generation 
antipsychotics do have some, however modest, effect on cognitive deficits, 
they far from satisfactorily alleviate these deficits (Gray and Roth, 2007, 
Mishara and Goldberg, 2004). New treatments for alleviating cognitive 
deficits and social dysfunctions are needed in order to capture what seems 
to be one of the core deficits of schizophrenia. In order to effectively 
screen and find new cognitive treatments for schizophrenia, the National 
Institute of Mental Health has developed a consensus battery Measures 
And Treatment Research to Improve Cognition in Schizophrenia 
(MATRICS) evaluating seven different cognitive domains (Green et al., 
2004, Green et al., 2005, Keefe et al., 2006, Nuechterlein et al., 2004). This 
initiative further highlights the importance of finding new ways of targeting 
the cognitive deficits and social dysfunctions of schizophrenia. Ongoing 
studies are evaluating the effects of several potential cognitive treatments 
targeting e.g. the DA, 5-HT, acetylcholine and GABA systems (Table 3). 
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Table 3: Potential new treatment targets for enhancing cognitive deficits in schizophrenia. 
Modified from Gray and Roth (2007). 
 
 
 
 
 
 
Mechanism of action  Example Compound  
D1 agonistsa  Dihydrexidine  
D4 antagonists  Sonepiprazole  
D4 agonists  A-412997  
COMT inhibitors  Tolcapone  
5-HT2A antagonists  M100907  
5-HT1A agonists  Tandospirone  
5-HT1A antagonists  WAY100635  
5-HT4 agonists  Tegaserod  
5-HT6 antagonists  SB-271046  
5-HT7 agonists  No selective ligands  
Cholinesterase inhibitors  Donepezil  
Nicotinic ?7 agonists  DMXB-A  
Nicotinic ? 4ß2 agonists  RJR2403  
M1 agonists  NDMC (nonselective)  
M4 agonists  No selective ligands  
M5 antagonists  No selective ligands  
NMDA enhancers  Glycine  
GlyT inhibitors  Org-24598  
Ampakines  CX-516  
mGluR2/3 agonists  Unknown  
mGluR5 agonists  CDPPB  
? 2-adrenergic antagonists  Guanfacine  
GABAA (? 2) agonists  TPA023  
GABAA (? 5) antagonists  L-655708  
Sigma agonists  No selective ligands  
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Schizophrenia remains an enigma encompassing the different aetiological 
factors including several different susceptibility genes, multiple 
neurochemical system implications, and diverse clinical symptoms. Thus it 
might be beneficial to treat different aspects of this disorder according to 
the nature of the symptoms using a symptom-specific approach. Such an 
approach would be to find a treatment that targets the core signalling 
system underlying a specific group of symptoms. Available antispychotics 
mainly targeting the DAergic system that seems to be the underlying core 
signalling system for positive symptoms. Regarding cognitive deficits, and 
perhaps also social dysfunctions, the core signalling system to target may 
be the NO signalling pathway as supported by the findings providing the 
basis for our “NO-dysregulation hypothesis for schizophrenia”. 
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